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Abstract 30 
Objective.  Neonatal screening for congenital adrenal hyperplasia (CAH) due to 21-31 
hydroxylase deficiency (21OHD) is mainly intended to prevent death due to salt wasting but 32 
remains controversial, because of the number of false-positive results and the ease with which 33 
most female cases can be identified by virilised genitalia at birth.  The aim of this study was 34 
to assess the efficiency of the national screening programme for 21OHD.  35 
Design.  Population-based study.  36 
Setting.  National neonatal screening program, paediatric endocrinologists nationwide 37 
and reference centre for genotyping.   38 
Participants.  All newborns screened for 21OHD in mainland France between 39 
January 1st, 1996 and December 31st 2003.  40 
Outcome Measures.  Screening efficiency indicators, disease severity and 41 
contribution of screening to early diagnosis, disease-specific mortality before and during the 42 
study period. 43 
Results.  6,012,798 newborns were screened, 15,407 were considered positive for 44 
21OHD and 383 cases were identified, giving a prevalence of 1/15,699 births.  The positive 45 
predictive value of screening was 2.3% (95% CI, 2.1-2.6), with a sensitivity of 93.5% (90.9-46 
95.9) and a specificity of 99.7%.  The false-positive rate was particularly high in preterm 47 
infants, for which the positive predictive value was 0.4% (0.2-0.5).  Screening allowed 48 
clinical diagnosis in 162 of 383 cases (42%), the others being detected clinically or through 49 
family history.  There was a trend towards declining neonatal mortality due to 21OHD.  50 
Conclusion.  In this large, population-based study, the efficiency of routine 21OHD 51 
screening was moderate in neonates born at term and very low in preterm neonates.  We 52 
recommend the discontinuation of screening, as performed here, in preterm newborns.  53 
 54 
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Introduction 55 
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of 56 
adrenal steroid biosynthesis 1-3.  The commonest form (≈95%) is due to 21-hydroxylase 57 
deficiency (21OHD).  It affects about one child in 15,000 and results in clinical symptoms 58 
that vary with the severity of the enzymatic defect.  Classical forms include salt-wasting 59 
forms (SW), for which there is a high risk of life-threatening adrenal insufficiency during the 60 
first month of life, and simple virilising forms (SV).  In both cases, female neonates present 61 
with markedly virilised external genitalia.  Non-classical forms can manifest with 62 
hyperandrogenism later in life and do not warrant early recognition through neonatal 63 
screening.  3β-hydroxysteroid dehydrogenase deficiency (3ß-HSD) is a rare form of CAH that 64 
results in the undervirilisation of external genitalia and adrenal insufficiency; it can be 65 
detected by 21OHD screening 4.  66 
21OHD screening is carried out to prevent neonatal death from acute adrenal 67 
insufficiency, inaccurate sex assignment in females with complete virilisation and irreversible 68 
childhood hyperandrogenism, which may result from incorrect or late diagnosis 3, 5.  21OHD 69 
fulfils the usual criteria 6 for neonatal screening, with its low cost and the availability of a 70 
widely applicable test (17-hydroxyprogesterone, 17-OHP, determination) and has been 71 
implemented in many Western countries including the USA and some European countries 3, 7-72 
9.  However, it remains controversial with three main arguments against routine screening: i) 73 
the test has a low positive predictive value, with frequent false-positive results in preterm 74 
neonates due to cross-reactions with steroids other than 17-OHP 10, ii) the proportion of cases 75 
for which screening really contributes to diagnosis is unclear, as most female cases are easy to 76 
detect clinically and salt-wasting is often detected before the screening results are obtained 77 
and iii) there is a lack of consensus concerning the 17-OHP threshold to be used, due to 78 
changes in 17-OHP distribution with gestational age at birth.   79 
4 
 
In France, 21OHD screening was introduced for all newborns as part of the national 80 
screening programme in 1996, after a short pilot feasibility study 11.  However, as in many 81 
other countries, routine 21OHD screening was never evaluated.  The main objective of this 82 
study was to evaluate the efficiency of the national French screening program for 21OHD.  83 
We retrospectively collected real-life screening data and clinical data for affected neonates, to 84 
determine whether screening by the Association Française pour le Dépistage et la Prévention 85 
des Handicaps de l'Enfant (AFDPHE), a national organisation, had facilitated the 86 
identification of cases before clinical diagnosis. 87 
88 
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Methods 89 
Population studied and data collected 90 
We carried out a retrospective study on all children born in mainland France between 91 
January 1st, 1996 and December 31st, 2003.  Screening was carried out at 21 regional centres, 92 
under the auspices of the Association Française pour le Dépistage et la Prévention des 93 
Handicaps de l'Enfant (AFDPHE) 12.  Blood was collected from three-day-old infants on filter 94 
paper and 17-OHP concentration was determined by automated time-resolved 95 
fluoroimmunoassay (DELFIA®) or RIA.  Infants with 17OHP levels above the threshold 96 
applied for screening purposes were evaluated further for the diagnosis of 21OHD.  We 97 
collected data from the regional centres on all newborns for whom 21OHD screening results 98 
were considered positive.  The data collected included date of birth, gestational age and birth 99 
weight, screening and repeat determinations of 17-OHP, assay and threshold used and final 100 
conclusions concerning the status of the child: affected with CAH (true positive), unaffected 101 
(false positive) or deceased.  17-OHP concentrations are expressed in nmol/l of blood and 102 
were converted if necessary (65 pg/spot = 80 nmol/l of blood).  The threshold applied was 103 
that recommended nationally by the AFDPHE, but was modified slightly at different times 104 
and in different regions, based on the local distribution of 17-OHP levels.  We collected 105 
additional data from the medical records of affected children, concerning sex, date, weight 106 
and plasma sodium concentration at diagnosis, genital abnormalities classified as described by 107 
Prader 1 and CYP21A2 genotyping results, classified as classical salt wasting (SW), classical 108 
simple virilising (SV) or non classical forms 13, 14.  If genotyping results were not available or 109 
not informative (n = 2) due to the detection of mutations with unknown functional 110 
repercussions, patients were classified as a function of the clinical data, leaving only one 111 
unclassified patient, who was then arbitrarily classified as affected with SW CAH.  Weight at 112 
diagnosis was expressed as a percentage of expected weight at a given age, based on birth 113 
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weight and the expected 1% gain in weight per day after day 8 15.  The distribution of the 114 
gestational ages of true negatives was derived from reference values published annually in 115 
France (DRESS 2001). 116 
We searched for false negatives (FN) detected before March 2010, which is at least six 117 
years after the birth of the last child studied, using five data sources: 1) regional screening 118 
centres notified of FN cases by physicians; 2) mail and e-mail surveys of all paediatric 119 
endocrinologists registered with the national society or treating children with CAH; 3) the 120 
French reference centre for CAH genotyping in Lyon and another molecular biology 121 
laboratory performing CAH genotyping and 4) the Centre for Epidemiology Medical Causes 122 
of Death database (CépiDc, INSERM), in which we looked for children dying from causes 123 
corresponding to International Classification of Diseases (ICD) 9 and 10 codes 255.2, 255.4, 124 
E25, E27.4 (adrenogenital disorders, other and unspecified adrenocortical insufficiency).  125 
Statistical analysis 126 
We calculated the sensitivity, specificity and predictive values of the screening test, 127 
with 95% confidence intervals (CI) for preterm neonates born before 37 weeks of gestational 128 
age, for term newborns, and for both considered together.  We classified the contribution of 129 
CAH screening to the diagnosis of true positives as follows: screening was considered useful 130 
if it led to the diagnosis of classical 21OHD (SW or SV forms) or 3ß-HSD deficiency that was 131 
not suspected clinically because there were no symptoms or because the symptoms and signs 132 
(genital abnormalities, dehydration) had not been recognised; screening was considered not 133 
useful if CAH was diagnosed before the results of screening became available (on the basis of 134 
family history, prenatal diagnosis or neonatal systematic examination).  Screening was also 135 
considered not useful for false negative cases of classical CAH and for children with positive 136 
screening results diagnosed with non-classical forms of CAH. 137 
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The relationship between gestational age at birth and 17-OHP concentration was 138 
studied by linear regression analysis in a sample of 10,523 preterm neonates born before 37 139 
weeks of amenorrhoea selected from the infants testing positive.  The values for 17-OHP 140 
concentration were not normally distributed and a natural logarithm transformation was 141 
therefore applied.  Goodness of fit (R2) was calculated for various linear regression models, to 142 
identify the factor best predicting 17-OHP concentration: gestational age or birth weight. 143 
Linear regression models were constructed for the imputation of missing data for term or birth 144 
weight. 145 
Mortality rates for children under the age of one year were calculated between 1979 146 
and 2007, from CepiDc data.  Changes in mortality rate over time were assessed by Poisson 147 
regression analysis.  We looked for a possible change in slope after 1996 (the year in which 148 
the screening programme was generalised), by looking for an interaction between “year”, 149 
considered as a continuous variable, and “before/after screening introduction” considered as a 150 
dichotomous variable.  151 
All analyses were performed with SAS 9.2 software (SAS Institute, Cary, NC, USA). 152 
The study was approved by the CCTIRS and CNIL and was conducted in accordance with 153 
French legislation.   154 
155 
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Results 156 
During the eight-year study period, 6,012,798 screening tests for 21OHD were 157 
performed on children born in mainland France (Figure 1, Table 1 and supplementary Table 158 
1).  The laboratory methods for 17-OHP determinations and their thresholds are shown in 159 
supplementary Table 1.  Neonatal screening tests were positive for 15,407 newborns, with 160 
370 considered affected, 11,324 considered unaffected and no conclusion reached by the 161 
screening centres for 3,132.  For 1,814 infants, the conclusion was discordant with the last 162 
recorded 17-OHP concentration (n = 338 considered unaffected with a last 17-OHP 163 
determination considered positive and n = 1476 considered unaffected without the recorded 164 
monitoring of 17-OHP concentrations). 581 children were identified as deceased :  most of 165 
these children were preterm and, in all cases, the death of the child was considered by clinical 166 
centres to be unrelated to 21OHD (Figure 1).  Most of the newborns with positive results for 167 
21OHD screening were born before term (91% of those for whom data were available).  The 168 
median day for filter paper sampling was day 4, although the screening protocol called for 169 
sampling on day 3. Of the 370 newborns considered to be affected, 358 had a classical form 170 
of 21OHD (n = 354) or 3βHSD (n = 4) deficiency and 12 had a non-classical form of CAH.  171 
The median age at diagnosis of CAH was seven days (Table 2).  Weight loss was 172 
severe (>10% of expected body weight) in 19% of those for whom data were available, and 173 
plasma sodium concentration was below 130 mmol/l in 18% of the infants.  Screening was 174 
useful for diagnosis in 162 of the 358 children with classical CAH and positive screening 175 
results, mostly males with the SW form (n = 106/162).  Screening results were positive but 176 
not useful for diagnosis in 74 children with a family history of 21OHD and in 96 girls with 177 
genital abnormalities detected during neonatal examination.  In addition, screening results 178 
were positive in 13 boys with classical 21OHD who were diagnosed clinically before the 179 
screening results became available.  Of interest, among the 38 premature babies with positive 180 
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screens, screening was useful to the diagnosis in only 13 among whom only 6 had a SW form.  181 
We identified 25 children as false negative for 21OHD screening: 23 were reported by 182 
genotyping laboratories, and 20 of these cases were also reported by the screening centres, 183 
with two reported by the CépiDC.  Most of the false negatives (16/25) had SV forms (Figure 184 
1).   185 
Altogether, the incidence of classical 21OHD (SW and SV forms) and 3ß-HSD 186 
deficiency in France between 0 and 1 year was 0.78/105 births/year, with a 95% CI of [0.70 – 187 
0.86] and the prevalence was 1/15699 births (95%CI, 1/17445 - 1/14269) (including false 188 
negative subjects in their birth cohort).  The sensitivity of screening was 93.5% with an 189 
overall positive predictive value of 2.3% (Table 3).  Sensitivity was higher for SW 21OHD 190 
(96.9%, 95%CI, 94.8-98.9) than for SV 21OHD (82.8%, 95%CI, 75.1-90.5).  Most false-191 
positive screening test results were obtained for preterm newborns, for which the positive 192 
predictive value of screening was only 0.36%, whereas that for term newborns was 30.4%.  193 
We investigated whether adjustment of the 17-OHP threshold would have improved screening 194 
efficiency in preterm newborns, by calculating linear regression models of (positive) 17-OHP 195 
levels on filter paper.  Gestational age accounted for 9.5% and weight accounted for 7.4% of 196 
the variance (R2) of 17-OHP concentration.  Adding polynomials and assay techniques 197 
increased the R2 to 10%.  Figure 2 illustrates the difficulty of establishing threshold values 198 
based on gestational age.  199 
As the primary objective of 21OHD screening is to prevent the death of newborns, we 200 
analysed 21OHD-related mortality in France from 1979 to 2007, a 29-year period including 201 
the year in which 21OHD screening was introduced.  Twenty-one children under the age of 202 
one year were classified with an underlying cause of death due to adrenogenital disorders, 203 
other and unspecified adrenocortical insufficiency (Figure 3).  There was a significant 204 
(p=0.002) trend towards a decrease in specific mortality rate during this period, with most of 205 
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this decrease occurring in 1991 to 1995, before the generalisation of screening.  Thus, neither 206 
screening itself (yes/no) nor the interaction of screening and time was associated with specific 207 
mortality rate (p=0.31 and 0.31, respectively).  208 
209 
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Discussion 210 
With the inclusion of 6,012,798 newborns screened in mainland France between 1996 211 
and 2003, this study is by far the largest to date to assess neonatal screening for 21OHD with 212 
particular emphasis on its contribution to early diagnosis.  We found that sensitivity was good 213 
(93%), but that the positive predictive value of screening was low (2.3%), although it 214 
improved markedly if we considered only term newborns (30.4%).  Screening results 215 
contributed to diagnosis in 42% of the cases.  Moreover, the large number of infants for which 216 
no conclusion was drawn raises questions about the practical organisation of 21OHD 217 
screening, due to the large number of false positives.  218 
Table 4 summarises published data from previous population studies, making 219 
comparisons with our results possible.  The positive predictive values reported in these studies 220 
were similar in most cases, with the exception of the Swiss study (positive predictive value of 221 
50%), which presented results for a second determination of 17-OHP on filter paper, rather 222 
than those for the primary screening, as in most studies.  Unlike previous studies, we took 223 
gestational age into account, and we found that screening efficiency differed considerably 224 
between term and preterm newborns.  Among preterm newborns, there were almost 277 false 225 
positives for each case of 21OHD discovered, whereas there were only two to three false 226 
positives for each case for term newborns.  These difficulties arise from the low specificity of 227 
immunological assay techniques for determining levels of 17-OHP in preterm newborns due 228 
to high plasma concentrations of steroids other than 17-OHP that cross-react in the assays 229 
(with sulphated metabolites), generating false-positive results 16-18.  Some countries have 230 
adopted variable threshold values based on gestational age (Table 4), but our study shows that 231 
there is a large overlap of 17-OHP levels between affected and unaffected preterm newborns 232 
and that increasing the threshold level in this particular population would result in a loss of 233 
sensitivity.  One possible alternative is the use of tandem mass spectrometry as a second line 234 
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test to improve the positive predictive value of screening 10, 19. These techniques were recently 235 
recommended in the Endocrine Society guidelines 3, but they are costly, not widely available 236 
for population screening and require thorough evaluation, including cost-benefit analyses. 237 
Although 21OHD screening correctly identified 93% of cases, its impact on diagnosis 238 
was much smaller, as it contributed to early diagnosis in 45 to 50% of the children identified, 239 
corresponding to about 20 children per year in France or an incidence of 2.66/105/year.  The 240 
main reasons for this minor contribution are that girls with classical 21OHD are readily 241 
identified during neonatal paediatric examination and CAH is an autosomal recessive 242 
disorder, making prenatal or neonatal diagnosis more likely in families with an index case.  In 243 
addition, in a small proportion of boys (9/153) with SW forms, adrenal crisis occurred before 244 
screening results became available and the children were correctly managed based on their 245 
clinical presentation.  246 
Screening for 21OHD is designed principally to decrease neonatal disease-specific 247 
mortality.  A decrease in specific mortality has been observed over the last three decades, but 248 
the timing of this decrease suggests that it was due to improvements in paediatric care rather 249 
than to the introduction of screening.  The probability of death due to neonatal adrenal crisis 250 
in the absence of screening is widely debated and has been reported to vary from 0 to 4% of 251 
patients with SW 21OHD in populations with high standards of clinical awareness and care 252 
for 21OHD 7.  In our study population of 285 children with salt-wasting 21OHD born 253 
between 1996 and 2003 (276 true positives and 9 false negatives), using 4% as an estimate 254 
suggests that 11.5 neonatal deaths would have been expected in the absence of screening, a 255 
figure to compare to 3 deaths observed during the first year of life.  In addition to preventing 256 
mortality, screening for 21OHD can prevent inaccurate gender assignment and irreversible 257 
childhood hyperandrogenism.  In our study, inaccurate gender assignment was not made in 258 
the 5 fully virilised females (Prader stage V) but screening allowed the identification of 47/77 259 
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patients with a SV form confirming the value of screening to detect the 21OHD before the 260 
appearance of severe hyperandrogenism.  261 
Our findings also show that the organisation of screening, as currently conducted in 262 
France (and possibly elsewhere), was not satisfactory.  Screening centres encountered major 263 
operational difficulties with follow-up of the large number of positive tests and no conclusion 264 
about status was reached in many cases, raising medical, ethical and responsibility issues.  265 
Questions remain concerning the fate of 307 children for whom successive assays remained 266 
above the threshold value but for whom no further follow-up data were obtained.  Data for 267 
weight and gestational age were also frequently missing, although this information makes it 268 
easier to interpret the assay results and should therefore be collected.  269 
Our study was subject to several limitations.  The apparent lack of impact of screening 270 
on mortality is likely due to insufficient statistical power, given the limited numbers in the 271 
mortality analysis (21 deaths in 29 years), the unmeasured effect of pilot 21OHD screening 272 
programs during the 1990-1995 period and more importantly undiagnosed 21OHD-related 273 
deaths in the period before screening as documented in central Europe 20.  In addition, 274 
inclusion in our analysis of misclassified adrenal diseases other than CAH might have 275 
obscured the effect of screening on mortality.  However, the study had sufficient power (80%) 276 
to detect a decrease in specific mortality of 65% or more after screening implementation.  We 277 
could not trace with precision the reasons for which false-negative cases were missed (17-278 
OHP concentration below the threshold, positive test not taken into account correctly, other 279 
reason).  False-negative cases may have been underestimated for several reasons, including 280 
lack of ascertainment if cases were detected later in life and not followed by paediatric 281 
endocrinologists or subjected to molecular analyses.  We were also unable to determine the 282 
number of unnecessary visits and laboratory investigations for children eventually found not 283 
to have 21OHD, or their impact on the anxiety of the parents.  Missing data on gestational age 284 
14 
 
may have resulted in an overestimation of the sensitivity of the screening, particularly in 285 
subgroup analysis (preterm and term newborns).  One further limitation is that data on 286 
neonatal screening from 1996-2003 are only presented in 2011, at a time when they might be 287 
considered less timely.  This apparent delay results from long and tedious data collection and 288 
monitoring and from the need to wait several years in order to be able to identify FN SV 289 
forms since the diagnosis is made as late as 5 or 6 years in some cases.  Indeed, we searched 290 
for FN cases in 2010, at a time when the youngest child in the cohort was older than 6 years, 291 
which is an additional strength of our study. 292 
In France, the budget per screened infant (for 21-OHD only) is €1.23 in the absence of 293 
follow-up (US$ 1.7), corresponding to approximately €924,500/year.  As ≈ 20 cases of 294 
21OHD are identified by screening each year, this budget corresponds to approximately 295 
€50,000 (US$ 70,000) per case.  In the US, the cost per screened infant without follow-up has 296 
been estimated at US$ 2.3 to 6.0 and applying these figures to our data would result in 297 
estimates of US$ 95,000 to 245,000 per case 21.  Assumptions concerning the number of 298 
potential deaths among these cases and a complete medical economic analysis of indirect 299 
costs might allow a full evaluation of the cost per life-year saved 21. 300 
Overall, we found that neonatal 21OHD screening was efficient in term newborns, 301 
with a variable impact on clinical management given that most affected female newborns are 302 
easy to identify without screening.  By contrast, the efficiency of screening was very low in 303 
preterm newborns, resulting in large numbers of false positives, flooding the system and 304 
leading to its dysfunction and leading to the identification of 6 cases of potentially lethal salt-305 
wasting 21OHD among more than 10,000 positives in 8 years.  Improved organisation might 306 
have prevented this dysfunction and allowed a comprehensive follow-up of all positive cases.  307 
However, a decrease of the false positive cases is necessary to improve efficiency.  308 
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So, what recommendations should be made based on our results?  We recommend that 309 
newborn screening for 21OHD is continued for term newborns in areas in which it is already 310 
performed and that careful consideration is given to its implementation in areas in which this 311 
is not the case.  By contrast, we recommend that 21OHD screening, as performed in this 312 
study, should not be carried out for preterm newborns since the positive predictive value of 313 
the test is very low and most preterm newborns are subject to careful paediatric care that 314 
should ensure that incipient salt wasting adrenal crises are readily recognised.  In France, the 315 
national neonatal screening organisation and representatives of professional organisations in 316 
neonatology, paediatric endocrinology and rare endocrine diseases are currently discussing 317 
how to improve the national screening program.  Our improved program, as well as others 318 
around the world will have to be carefully evaluated.   319 
320 
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Gaucherand, Prof. Debillon; CH de Chambery, Dr Vercherat. 368 
Laboratories who conducted the genotyping  369 
Prof. Morel, Dr Tardy, Lyon; Dr Bellane-Chantelot, Paris-Pitié Salpétrière; Prof. Clauser, Paris-Cochin. 370 
Physicians who participated in the evaluation and management of screened newborns  371 
Dr Adiceam, Aix-en-Provence; Dr Boudailliez, Amiens; Prof. Coutant, Angers; Dr Duquesne, Auch; Dr 372 
Vedrenne, Avon; Dr Pincemaille, Bastia; Dr Carre, Bayonne; Dr Bertrand, Besançon; Dr Dieckmann, Blois; Dr 373 
Sauvion, Bondy; Dr Barat, Bordeaux; Dr Llanas, Bordeaux; Dr Sarlangue, Bordeaux; Dr Riviere, Bourges; Dr 374 
Giroux, Brest; Dr Metz, Brest; Dr Cuvelier, Calais; Dr Elchardus, Charleville-Mézières; Dr Ezzeddine, 375 
Charleville-Mézières; Dr Phan, Chartres; Dr Benchekroun, Châteauroux; Dr Carla, Clermont-Ferrand; Dr 376 
Pennerath, Colmar; Dr Vervel, Compiègne; Dr Chevrel, Dax; Dr Jeannot, Dieppe; Dr de Monleon, Dijon; Dr 377 
Gounot, Dijon; Prof. Huet, Dijon; Dr Loeuille, Dunkerque; Dr Dulucq, Epinal; Dr Kozisek, Flers; Dr Al-Issa, 378 
Fontainebleau; Dr Tommasi, Grasse; Dr Dupuis, Grenoble; Dr Pigeon, Hazebrouck; Dr Brossier, La-Roche-sur-379 
Yon; Prof. Brauner, Le-Kremlin-Bicêtre; Dr Bonardi, Le-Mans; Dr Maxaud, Le-Mans; Dr Souto, Le-Mans; Dr 380 
Chauvet, Lens; Dr Guemas, Lens; Dr Boulard, Libourne; Dr Cartigny-Maciejewski, Lille; Prof. Lienhardt, 381 
Limoges; Dr Ribault, Lisieux; Dr Naud-Saudreau, Lorient; Dr Berlier, Lyon; Prof. Chatelain, Lyon; Dr Nicolino, 382 
Lyon; Dr Simonin, Marseille; Dr Mathivon, Meaux; Dr Pignol, Mont-De-Marsan; Dr Arzim, Montélimar; Dr 383 
Jeandel, Montpellier; Prof. Sultan, Montpellier; Dr Benoit, Mulhouse; Dr Baron, Nantes; Dr Ramos, Nantes; Dr 384 
Baechler-Sadoul, Nice; Dr Wagner, Nice; Dr Zelinsky, Niort; Dr Monceaux, Orléans; Dr Moretti, Orsay; Dr 385 
Beaussac, Paimpol; Dr Cabrol, Paris; Prof. Leger, Paris; Dr Morel-Bouvattier, Paris; Prof. Polak, Paris; Dr 386 
Pradeaux, Perigueux; Dr Barba, Pessac; Dr Puel, Pessac; Dr Crosnier, Poissy; Dr Sarda, Pontoise; Dr Queinnec, 387 
Quimper; Dr Sulmont, Reims; Dr de Kerdanet, Rennes; Dr Jeannoel, Roanne; Dr Ythier, Roubaix; Prof. Mallet, 388 
Rouen; Dr Idres, Saint-Brieux; Dr Raynaud-Ravni, Saint-Etienne; Dr Chouraki, Saint-Quentin; Dr Garandeau, 389 
StDenis-LaRéunion; Dr Soskin, Strasbourg; Dr Petrus, Tarbes; Dr Feldmann, Thionville; Dr Lambert-Leonardi, 390 
Thionville; Dr Jesuran-Perelroizen, Toulouse; Prof. Tauber, Toulouse; Dr Despert, Tours; Dr Ceccato, Tresses; 391 
Dr Jullien, Troyes; Dr Ninot, Troyes; Dr Soulier, Tulle; Dr Leheup, Vandoeuvres LesNancy; Dr Goldfarb, 392 
Vannes; Dr Goumy, Vichy; Dr Rebaud, Villefranche-Sur-Saone; Dr Roubin, Villeneuve-Sur-Lot.  393 
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Legends for figures 460 
 461 
Figure 1. Results of neonatal screening for 21-hydroxylase deficiency in France 1996-2003 462 
 463 
 464 
Figure 2.  17-OHP concentration (nmol/l) at neonatal screening in affected and unaffected (false-465 
positive) children as a function of gestational age 466 
Individual values for affected children are shown as red dots  and those for false positives are 467 
shown as green dots .  468 
 469 
 470 
Figure 3.  Specific mortality rates due to adrenogenital disorders, other and unspecified 471 
adrenocortical insufficiency during the first year of life in France, 1979-2007. 472 
 473 
 474 
475 
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Table 1 – Principal characteristics of newborns with positive screening results for CAH 476 
in mainland France between 1996 and 2003 477 
 478 
 N = 15,407 
Sex  
 Male 9,031 (59) 
 Female 6,218 (41) 
Gestational age (WA)†* 31 (28 – 34) 
 Preterm (<37 WA) 
 Term (≥37 WA) 
 Missing data 
10,563 (68) 
1,058 (7) 
3,786 (25) 
Birth weight (g)†* 1,490 (1,005 – 2,090) 
Age at screening (days)† 4 (3-5) 
17-OHP screening result (nmol/l)† 80 (65-109) 
17-OHP measurement method used 
 Radioimmunoassay 
 DELFIA® 
 
8,457 (55) 
6,945 (45) 
 479 
Data are presented as numbers (percentages) unless otherwise stated; †, median, interquartile range; WA: weeks 480 
of amenorrhoea; * imputations of gestational age from sex and birth weight: n = 998, imputations of birth weight 481 
from sex and gestational age: n = 2653; † missing data: sex n = 158; age at screening n = 1117; 17-OHP 482 
screening result n = 72; 17-OHP measurement method n = 5. 483 
 484 
485 
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Table 2 – Characteristics of affected newborns with CAH due to classical 21OHD or 3ß-486 
HSD detected by screening in mainland France between 1996 and 2003  487 
 True positives  
(n = 358) 
Sex  
 Boys 205 (57) 
 Girls 153 (43) 
Gestational age (WA)† 
 Preterm (<37 WA) 
 Term (≥37 WA) 
39 (38-40) 
38 (10.7) 
318 (89.3) 
Birth weight (g)† 3,370 (2,980 – 3,680) 
Age at screening (days)† 3 (3-4) 
Age at diagnosis (days)† 7 (1-10) 
Contribution of screening to the diagnosis of CAH, n (M/F)  
 Useful 
 Salt-wasting 21OHD 
 Simple virilising 21OHD 
 3ß-HSD 
162 (137/25) 
114 (106/8) 
47 (30/17) 
1 (1/0) 
 Not useful* 
  Clinical diagnosis before screening results 
     Salt-wasting 21OHD 
  Simple virilising 21OHD 
  3ß-HSD 
  Prenatal diagnosis or family history 
     Salt-wasting 21OHD 
  Simple virilising 21OHD 
  3ß-HSD 
196 (68/128) 
109 (13/96) 
99 (9/90) 
8 (2/6) 
2 (2/0) 
74 (46/28) 
54 (33/21) 
20 (13/7) 
0 (0/0) 
 Information on usefulness unavailable 
     Salt-wasting 21OHD 
  Simple virilising 21OHD 
   3ß-HSD 
13 (9/4) 
10 (6/4) 
2 (2/0) 
1(1/0) 
Plasma sodium concentration at diagnosis (nmol/l)†
≥135 
130-135 
<130 
 
177 (78M/99F) 
80 (61M/19F) 
56 (48M/8F) 
Relative weight change at diagnosis (% of expected)† 
 ≥0% 
 [0; -5%] 
 [-5; -10%] 
 <-10% 
 
42 (21/21) 
62 (34/28) 
76 (60/16) 
42 (39/3) 
 488 
Data are presented as numbers (percentages) unless otherwise stated; †, median, interquartile range; WA: weeks 489 
of amenorrhoea; SD: Standard deviation; missing data: gestational age, n=2; age at screening, n = 28; age at 490 
diagnosis, n = 38; plasma sodium concentration, n = 47; relative weight change at diagnosis, n = 138.  The 25 491 
false-negative cases (11 boys and 14 girls), for whom screening was not useful, are not included in this table.  492 
493 
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Table 3. Efficiency of 21OHD screening as a function of gestational age at birth 494 
 Table 3a: Raw data 495 
 Screening Affected Unaffected Total 
A
ll 
ne
w
bo
rn
s 
Positive  358  15,049 15,407 
Negative  25 5,997,366 5,997,391 
Total 383 6,012,415 6,012,798 
T
er
m
 
ne
w
bo
rn
s 
(≥3
7 
W
A
) 
Positive  318 740 1058 
Negative  21 5,578,196 5,578,217 
Total 339 5,578,936 5,579,275 
Pr
et
er
m
 
ne
w
bo
rn
s 
(<
37
 W
A
) 
Positive  38 10,524 10,562 
Negative  2 422,959 422,961 
Total 40 433,383 433,523 
 496 
 Table 3b: Efficiency calculations 497 
A
ll 
ne
w
bo
rn
s Positive predictive value 2.3 [2.1-2.6] Specificity 99.7 [99.7 - 99.7] 
Negative predictive value 99.9 [99.9 - 99.9] Sensitivity 93.5 [90.9 – 95.9] 
T
er
m
 
ne
w
bo
rn
s 
(≥3
7 
W
A
) Positive predictive value 30.1 [27.3-32.8] Specificity 99.9 [99.9-99.9] 
Negative predictive value 99.9 [99.9 ; 99.9] Sensitivity 93.8  [91.2-96.4] 
Pr
et
er
m
 
ne
w
bo
rn
s 
(<
37
 W
A
) Positive predictive value 0.4 [0.2-0.5] Specificity 97.6 [99.5-97.6] 
Negative predictive value 99.9 [99.9 ; 99.9] Sensitivity 95 [83.1 -99.4] 
 498 
Data are expressed in % [95% confidence interval]; efficiency in term and preterm newborns was calculated for 499 
those without missing data for gestational age at birth (11,620/15,407).  500 
501 
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Table 4.  Efficiency of 21OHD screening in published studies 502 
Reference Country Number of newborns 
17-OHP 
threshold 
(nmol/l) 
Variable 17-OHP 
threshold with 
term 
Sensitivity 
(%) 
Positive 
predictive 
value (%) 
22 USA (Texas) 1,936,998 123 yes 86 NA 
11 France 408,138 36 to 60 no 89 2.1 
23 Switzerland 333,221 30 to 90 yes 97 50.0 
24 Netherlands 176,684 60 yes 100 5.9 
25 Italy 128,330 36 yes NA 1.9 
This study France 6,012,798 40 to 100 no 93 2.3 
 503 
Population-based studies with a sample size >100 000 were selected  504 
505 
25 
 
Supplementary Table 1: Thresholds and laboratory methods used for 17-OHP 506 
determination 507 
 508 
Methods and thresholds Number of newborns who 
screened positive , n (%) 
Delfia®* 6,945 (45.1) 
 40 nmol/l
 50 nmol/l
 60 nmol/l
 70 nmol/l
595 
3,209 
1,416 
1,725 
RIA* 8,457 (54.9) 
 50 nmol/l
 60 nmol/l
 70 nmol/l
 80 nmol/l
 100 nmol/l
 50 pg/spot
 60 pg/spot
 70 pg/spot
1,572 
4,050 
1,209 
87 
78 
1,124 
34 
303 
 509 
*Delfia®, dissociation-enhanced lanthanide fluorescence immunoassay; RIA, radioimmunoassay; missing data: 510 
Laboratory methods, n = 5, thresholds n = 5. 511 
 512 
Newborns screened for 21OHD in France between 1996 – 2003
N = 6 012 798
Considered as negative
N = 5 997 391
Considered as positive
N = 15 407
False negatives (M/F)
N = 25
Simple Virilizing CAH due to
Salt-wasting CAH due to
21-OH deficiency
N =  9 (7/2)
Affected with CAH
N = 370 (M/F)
Unaffected
N = 11 324
Deceased
N = 581
No conclusion
N = 3 132
-    
21-OH deficiency
N = 16 (4/12)
Last 17-OHP value 
>cutoff
N = 338
Last 17-OHP value 
≤cutoff
N = 9510
No monitoring of
Last 17-OHP value 
>cutoff
N = 307
No monitoring of
Salt-wasting CAH due to
21-OH deficiency
N = 277 (154/123) 
Simple-virilizing CAH 
due to 21-OH deficiency
N = 77 (47/30) 
CAH due to    
17-OHP value
N = 1476
   
17-OHP value
N = 2825
  
3ß-HSD deficiency
N = 4 (4/0)
Non classical CAH due
to  21-OH deficiency
N = 12 (4/8) 
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